Ricky Goldwasser
Stock Analyst at Morgan Stanley
(3.80)
# 563
Out of 4,789 analysts
246
Total ratings
62.96%
Success rate
20.27%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $220 → $184 | $150.52 | +22.24% | 20 | Feb 5, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $260 → $270 | $232.74 | +16.01% | 15 | Dec 17, 2024 | |
| ACCD Accolade | Maintains: Equal-Weight | $6 → $5 | $6.98 | -28.37% | 17 | Dec 17, 2024 | |
| DOCS Doximity | Upgrades: Equal-Weight | $33 → $53 | $58.03 | -8.67% | 9 | Nov 14, 2024 | |
| UNH UnitedHealth Group | Maintains: Overweight | $615 → $610 | $523.75 | +16.47% | 15 | Oct 16, 2024 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $6.66 | +50.15% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $4.41 | +24.72% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $13.11 | -42.79% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $18.62 | -35.55% | 8 | Aug 30, 2023 | |
| CNC Centene | Downgrades: Equal-Weight | $94 → $73 | $60.71 | +20.24% | 10 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $145 | $169.20 | -14.30% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $329.39 | +10.81% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $672.99 | -37.59% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $7.88 | +1,422.84% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $264.60 | +134.32% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $434.96 | +14.95% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $67.75 | +83.03% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $329.00 | -3.34% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $137.77 | -49.19% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $43 → $39 | $11.17 | +249.15% | 15 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $176.30 | +10.61% | 6 | Oct 21, 2020 | |
Charles River Laboratories International
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $220 → $184
Current: $150.52
Upside: +22.24%
Labcorp Holdings
Dec 17, 2024
Maintains: Overweight
Price Target: $260 → $270
Current: $232.74
Upside: +16.01%
Accolade
Dec 17, 2024
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $6.98
Upside: -28.37%
Doximity
Nov 14, 2024
Upgrades: Equal-Weight
Price Target: $33 → $53
Current: $58.03
Upside: -8.67%
UnitedHealth Group
Oct 16, 2024
Maintains: Overweight
Price Target: $615 → $610
Current: $523.75
Upside: +16.47%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $6.66
Upside: +50.15%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $4.41
Upside: +24.72%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $13.11
Upside: -42.79%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $18.62
Upside: -35.55%
Centene
Aug 30, 2023
Downgrades: Equal-Weight
Price Target: $94 → $73
Current: $60.71
Upside: +20.24%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $169.20
Upside: -14.30%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $329.39
Upside: +10.81%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $672.99
Upside: -37.59%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $7.88
Upside: +1,422.84%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $264.60
Upside: +134.32%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $434.96
Upside: +14.95%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $67.75
Upside: +83.03%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $329.00
Upside: -3.34%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $137.77
Upside: -49.19%
Jul 6, 2022
Maintains: Underweight
Price Target: $43 → $39
Current: $11.17
Upside: +249.15%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $176.30
Upside: +10.61%